MCID: ATS008
MIFTS: 42

Autosomal Dominant Disease malady

Category: Genetic diseases (common)

Aliases & Classifications for Autosomal Dominant Disease

About this section

Aliases & Descriptions for Autosomal Dominant Disease:

Name: Autosomal Dominant Disease 11 13
 
Autosomal Dominant Disorder 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:0050736

Summaries for Autosomal Dominant Disease

About this section
Disease Ontology:11 An autosomal genetic disease that is characterized by the presence of one disease-associated mutation of a gene which is sufficient to cause the disease.

MalaCards based summary: Autosomal Dominant Disease, also known as autosomal dominant disorder, is related to beare-stevenson cutis gyrata syndrome and aromatase excess syndrome. An important gene associated with Autosomal Dominant Disease is ALX4 (ALX Homeobox 4), and among its related pathways are Glypican 3 network and Platinum Pathway, Pharmacokinetics/Pharmacodynamics. Affiliated tissues include kidney, liver and bone, and related mouse phenotypes are hearing/vestibular/ear and no phenotypic analysis.

Related Diseases for Autosomal Dominant Disease

About this section

Diseases related to Autosomal Dominant Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 139)
idRelated DiseaseScoreTop Affiliating Genes
1beare-stevenson cutis gyrata syndrome31.4FGFR2, FGFR3, MSX2
2aromatase excess syndrome11.0
3episodic ataxia10.8
4polycystic kidney disease, adult type i10.8
5storm syndrome10.7
6epstein syndrome10.7
7angioimmunoblastic lymphadenopathy with dysproteinemia10.7MLH1, MSH2
8spleen angiosarcoma10.7MLH1, MSH2, MSH6
9pityriasis rosea10.7MLH1, MSH2
10craniosynostosis 510.7ALX4, MSX2
11food allergy10.7MLH1, MSH2, MSH6
12solitary bone cyst10.7MLH1, MSH2, MSH6
13optic papillitis10.7MLH1, MSH2, MSH6
14cardiomyopathy, hypertrophic, 410.7ALX4, MSX2
15hyperaldosteronism10.7MLH1, MSH2, PAX3
16pasli disease10.7FGFR3, MSH2
17glucocorticoid resistance10.7
18polycystic kidney disease 210.6
19arrhythmogenic right ventricular cardiomyopathy10.6MLH1, MSH2, MSH6
20frontonasal dysplasia 210.6ALX4, MSX2
21trachea sarcoma10.6MLH1, MSH2, MSH6
22flnb-related disorders10.6FGFR2, FGFR3
23cervical adenomyoma10.6MLH1, MSH2
24plasmalogens synthesis deficiency isolated10.6FGFR2, FGFR3
25pediculus humanus capitis infestation10.6HMBS, MLH1
26dysostosis10.6MLH1, MSH2, MSH6
27pelizaeus-merzbacher disease in female carriers10.6PTCH1, SHH
28x-linked dominant intellectual disability-epilepsy syndrome10.6PTCH1, SHH
29large intestine adenocarcinoma10.6MLH1, MSH2, MSH6, PMS2
30hereditary essential tremor 510.6MLH1, MSH2, MSH6, PMS2
31subependymal glioma10.6MLH1, MSH2, MSH6, PMS2
32muir-torre syndrome10.6MLH1, MSH2, MSH6, PMS2
33neurofibromatosis-noonan syndrome10.6MLH1, MSH2, MSH6, PMS2
34cerebellar disease10.6MLH1, MSH2, MSH6, PMS2
35trigonocephaly 110.6FGFR2, FGFR3
36tumor predisposition syndrome10.6MLH1, MSH2, MSH6, PMS2
37acquired amegakaryocytic thrombocytopenia10.6MSH2, MSH6
38in situ carcinoma10.6MLH1, MSH2, MSH6, PMS2
39mite infestation10.5FGFR2, FGFR3
40prostate embryonal rhabdomyosarcoma10.5MSH2, MSH6, PAX3, PMS2
41colver steer godman syndrome10.5MLH1, MSH2
42pleomorphic rhabdomyosarcoma10.5PAX3, PTCH1, YAP1
43basal cell nevus syndrome10.5
44popliteal pterygium syndrome 110.5
45colorectal cancer, hereditary nonpolyposis, type 810.5
46colorectal cancer, hereditary nonpolyposis, type 510.5
47fibrodysplasia ossificans progressiva10.5
48erythermalgia, primary10.5
49corneal fleck dystrophy10.5
50craniofacial-deafness-hand syndrome10.5

Graphical network of the top 20 diseases related to Autosomal Dominant Disease:



Diseases related to autosomal dominant disease

Symptoms & Phenotypes for Autosomal Dominant Disease

About this section

MGI Mouse Phenotypes related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

41 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.9FGFR2, FGFR3, GJB2, MSX2, PAX3, SHH
2MP:00030129.6EPCAM, FGFR2, FGFR3, GJB2, PAX3, PTCH1
3MP:00053889.5ALX4, FGFR2, FGFR3, PAX3, PTCH1, SHH
4MP:00053719.3ALX4, FGFR2, FGFR3, GJB2, MSX2, PAX3
5MP:00053679.2FGFR2, FGFR3, HMBS, PAX3, PTCH1, SHH
6MP:00053829.2ALX4, FGFR2, FGFR3, GJB2, MSX2, PAX3
7MP:00053699.1ALX4, FGFR2, HMBS, MSX2, PAX3, PTCH1
8MP:00020069.1FGFR2, FGFR3, MLH1, MSH2, MSH6, PAX3
9MP:00053909.1ALX4, FGFR2, FGFR3, GJB2, MSX2, PAX3
10MP:00053919.1ALX4, FGFR2, FGFR3, GJB2, MLH1, MSX2
11MP:00028739.0ALX4, FGFR2, FGFR3, GJB2, HMBS, MSX2
12MP:00053979.0EPCAM, FGFR2, FGFR3, MSH2, MSX2, PAX3
13MP:00053809.0ALX4, DLX3, EPCAM, FGFR2, GJB2, MSX2
14MP:00053798.8DLX3, EPCAM, FGFR2, MLH1, MLH3, MSX2
15MP:00053848.5EPCAM, FGFR2, FGFR3, GJB2, MLH1, MSH2
16MP:00053878.4EPCAM, FGFR2, FGFR3, GJB2, MSH2, MSX2
17MP:00053868.4ALX4, EPCAM, FGFR2, FGFR3, HMBS, MLH1
18MP:00107718.4ALX4, DLX3, FGFR2, FGFR3, GJB2, MLH1
19MP:00053858.3DLX3, EPCAM, FGFR2, GJB2, MSX2, PAX3
20MP:00053788.2ALX4, DLX3, EPCAM, FGFR2, FGFR3, GJB2
21MP:00053768.2EPCAM, FGFR2, FGFR3, GJB2, HMBS, MLH1
22MP:00036318.1ALX4, EPCAM, FGFR2, FGFR3, GJB2, HMBS
23MP:00053818.0ALX4, EPCAM, FGFR2, FGFR3, MLH1, MSH2
24MP:00107687.6ALX4, DLX3, EPCAM, FGFR2, FGFR3, GJB2

Drugs & Therapeutics for Autosomal Dominant Disease

About this section

Drugs for Autosomal Dominant Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 215)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EverolimusapprovedPhase 4, Phase 2, Phase 3, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
2
CandesartanapprovedPhase 4, Phase 2156139481-59-72541
Synonyms:
139481-59-7
2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid
2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
AC-203
AC1L1DWT
Amias
Atacand
Atacand, Blopress, Amias, Ratacand,Candesartan
BIDD:GT0350
Blopress
Blopress (TN)
C07468
C081643
C24H20N6O3
CHEBI:216848
 
CHEBI:3347
CHEMBL1016
CID2541
CV 11974
CV-11974
CV11974
Candesartan (USAN/INN)
Candesartan [BAN]
Candesartan [USAN:INN]
Candesartan cilexetil
D00522
DB00796
FT-0083585
HMS2089M22
HSDB 7520
I01-0374
KS-5003
L000156
LS-32740
MolPort-003-845-570
MolPort-005-943-739
NCGC00167474-01
Ratacand
S1578_Selleck
TL8000897
UNII-S8Q36MD2XX
candesartan
3
CilnidipineapprovedPhase 4, Phase 28132203-70-45282138
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC-270
AC1NQZJB
Atelec
Atelec (TN)
BRD-A07875874-001-01-6
Bio-0164
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
 
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
STK623341
Siscard
cilnidipine
4
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
5
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
6
Methylphenidateapproved, investigationalPhase 4373113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
7
DopamineapprovedPhase 4, Phase 3, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
8
Celiprololapproved, investigationalPhase 4256980-93-9
Synonyms:
 
RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
9Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 13615
10Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
11Antirheumatic AgentsPhase 4, Phase 2, Phase 110627
12Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
13Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
14Adrenergic AgentsPhase 4, Phase 35140
15Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
16Angiotensin Receptor AntagonistsPhase 4, Phase 3, Phase 21173
17
Angiotensin IIPhase 4, Phase 3, Phase 2116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
18Adrenergic AntagonistsPhase 41535
19Adrenergic alpha-AntagonistsPhase 4727
20Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2711
21Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 31078
22AngiotensinogenPhase 4, Phase 3, Phase 21161
23
Candesartan cilexetilPhase 4, Phase 2156145040-37-52540
Synonyms:
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
145040-37-5
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
AC-204
AC1L1DWQ
ATACAND HCT
Almirall brand of candesartan cilexetil
Amias
Astra brand of candesartan cilexetil
AstraZeneca brand of candesartan cilexetil
Atacand
Atacand (TN)
BRD-A65671304-001-02-6
BSPBio_002691
C07709
C077793
C33H34N6O6
CHEBI:216349
CHEMBL1014
CID2540
Candesartan cilexetil
Candesartan cilexetil (JAN/USAN)
Candesartan cilexetil [USAN]
Candesartan hexetil
D00626
FT-0082579
H212/91
 
HMS1922J09
HMS2093E20
I06-0090
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
KBioGR_001607
KBioSS_002187
Kenzen
L006257
LS-32741
MolPort-003-666-552
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
Parapres
Promed brand of candesartan cilexetil
Racanda
SPBio_000349
SPECTRUM1504261
ST51052687
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
Spectrum_001707
TCV 116
TCV-116
TL8000995
Takeda brand of candesartan cilexetil
UNII-R85M2X0D68
candesartan cilexitil
24calcium channel blockersPhase 4, Phase 3, Phase 21940
25Calcium, DietaryPhase 4, Phase 3, Phase 25525
26Antihypertensive AgentsPhase 4, Phase 3, Phase 24095
27Vasodilator AgentsPhase 4, Phase 23438
28AnalgesicsPhase 4, Phase 211287
29Analgesics, Non-NarcoticPhase 4, Phase 26260
30Autonomic AgentsPhase 4, Phase 3, Phase 29774
31Anti-Inflammatory AgentsPhase 4, Phase 210355
32Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 24295
33Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
34Dopamine Uptake InhibitorsPhase 41305
35Central Nervous System StimulantsPhase 42132
36Anti-Arrhythmia AgentsPhase 42969
37Neurotransmitter AgentsPhase 4, Phase 2, Phase 317734
38Dopamine AgentsPhase 4, Phase 3, Phase 23759
39Neurotransmitter Uptake InhibitorsPhase 4, Phase 33464
40Adrenergic beta-1 Receptor AntagonistsPhase 4350
41Adrenergic beta-AntagonistsPhase 41154
42
CurcuminPhase 4137458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
43
lanreotideapprovedPhase 2, Phase 382108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
44
Telmisartanapproved, investigationalPhase 3264144701-48-465999
Synonyms:
144701-48-4
2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
AC-2013
AC1L24EB
AC1Q5U7O
Abbott brand of telmisartan
BAY-68-9291
BAY68-9291
BIBR 277
BIBR 277SE
BIBR-277
BIBR-277-SE
BIBR-277SE
BIDD:GT0365
BRD-K73999723-001-02-2
BSPBio_002738
Bay 68-9291
Bio-0103
Boehringer Ingelheim brand of telmisartan
C07710
C084178
C33H30N4O2
CHEBI:9434
CHEMBL1017
CID65999
CPD000466326
D00627
DB00966
Glaxo Wellcome brand of telmisartan
GlaxoSmithKline brand of telmisartan
 
HMS1922P07
HMS2051P16
HMS2090P17
HMS2093M22
HSDB 7590
I06-0281
KBio3_001958
KBioGR_001842
Kinzal
Kinzalmono
L001035
LS-44263
MLS000759432
MLS001076687
Micardis
Micardis (TN)
Micardis HCT
Micardis, Targit, Temax, BIBR277, Telmisartan
MolPort-003-666-621
NCGC00095150-01
NCGC00095150-02
NCGC00095150-03
Pritor
S1738_Selleck
SAM001246602
SMR000466326
SPBio_002131
SPECTRUM1505261
STK624049
Spectrum2_001976
Spectrum3_001089
Spectrum4_001261
Spectrum5_001053
TL8000991
Telmisartan
Telmisartan (JAN/USAN/INN)
Telmisartan [USAN:INN]
UNII-U5SYW473RQ
YM-086
telmisartan
45
MipomersenapprovedPhase 3, Phase 2191000120-98-8
Synonyms:
 
Kynamro
46
PravastatinapprovedPhase 314981093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
47
Riluzoleapproved, investigationalPhase 2, Phase 3631744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
48
ClonidineapprovedPhase 32264205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
49
Metoprololapproved, investigationalPhase 320137350-58-6, 51384-51-14171
Synonyms:
(+/-)-Metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol
1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol
3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
37350-58-6
51384-51-1
54163-88-1
AB00053499
AC-19022
AC1L1HKM
AstraZeneca Brand of Metaoprolol Tartrate
AstraZeneca Brand of Seloken
BRD-A03623303-045-02-0
Beatrolol
Beloc
Beloc Duriles
Beloc-Duriles
BelocDuriles
Betaloc
Betaloc Astra
Betaloc-Astra
BetalocAstra
Betalok
C07202
CCRIS 4198
CGP 2175
CGP-2175
CGP2175
CHEBI:6904
CHEMBL13
CID4171
D008790
D02358
DB00264
DL-metoprolol
Dl-Metoprolol
Dutoprol
EINECS 253-483-7
EINECS 257-166-4
H 93 26
H 93-26
H 9326
 
HMS2090B15
HSDB 6531
I01-7125
I06-0125
Jsp006606
L000669
LOPRESSIDONE
LS-122450
Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate
Lopresor
Lopresoretic
Lopressor
Lopressor HCT
Meijoprolol
Metohexal
Metoprolol
Metoprolol (USAN/INN)
Metoprolol Tartrate
Metoprolol [USAN:INN:BAN]
Metoprolol slow release
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metoprololum [INN-Latin]
Metroprolol
MolPort-005-938-039
NCGC00021148-02
NCGC00021148-03
NCGC00021148-04
Novartis Brand of Metprolol Tartrate
Preblok
Prelis
Presolol
Selo-Zok
Seloken
Seloken AstraZeneca Brand
Selopral
Seroken
Spesicor
Spesikor
TOPROL-XL
Tartrate, Metoprolol
Toprol
Toprol XL
Toprol-XL
UNII-GEB06NHM23
dl-Metoprolol
metoprolol
50
MinoxidilapprovedPhase 33438304-91-54201
Synonyms:
16317-69-4
2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine
2,4-Diamino-6-piperidinilpirimidina-3-ossido
2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]
2,4-Diamino-6-piperidino-pyrimidine-3-oxide
2,4-Diamino-6-piperidinopyrimidine 3-N-oxide
2,4-Diamino-6-piperidinopyrimidine 3-oxide
2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide
2,6-Diamino-4-piperidinopyrimidin-1-oxid
3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine
3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
38304-91-5
5-25-12-00317 (Beilstein Handbook Reference)
6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide
6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide
6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine
6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
6-Piperidino-2,4-diaminopyrimidine 3-oxide
6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
AB00513797
AC-5271
AC1L1HN1
Alopexil
Alostil
Ambap38304-91-5
Apo-Gain
Apo-gain
BCBcMAP01_000193
BPBio1_000065
BRD-K06902185-001-05-2
BRD-K14888893-001-02-3
BRN 0886240
BSPBio_000059
BSPBio_001385
BSPBio_002037
Bio1_000084
Bio1_000573
Bio1_001062
Bio2_000105
Bio2_000585
C9H15N5.H2O
CAS-38304-91-5
CBiol_001798
CHEBI:49774
CHEBI:6942
CHEMBL609587
CHEMBL802
CID4201
CPD-7668
CPD000058963
D00418
D008914
DB00350
DB08225
DivK1c_000160
EINECS 253-874-2
EU-0100786
Gen-Minoxidil
HMS1361F07
HMS1568C21
HMS1791F07
HMS1920P03
HMS1989F07
HMS2089L08
HMS2091F20
HMS500H22
HSDB 6538
IDI1_000160
IDI1_033855
Jsp006715
KBio1_000160
KBio2_000105
KBio2_001449
KBio2_002673
KBio2_004017
KBio2_005241
KBio2_006585
KBio3_000209
KBio3_000210
KBio3_001537
KBioGR_000105
KBioGR_000585
KBioSS_000105
KBioSS_001449
LS-135040
Loniten
Loniten (TN)
Lonolox
Lopac-M-4145
 
Lopac0_000786
M 4145
M1389
MINOXIDIL (FOR MEN)
MINOXIDIL (FOR WOMEN)
MINOXIDIL EXTRA STRENGTH (FOR MEN)
MINOXIDIL EXTRA STRENGTH FOR MEN
MLS000028566
MLS000859953
MLS001077294
Men s Rogaine Foam
Men's Rogaine
Mens Rogaine Foam
Minodyl
Minossidile
Minossidile [Italian]
Minoxidil
Minoxidil (USP/INN)
Minoxidil Pfizer Brand
Minoxidil [USAN:BAN:INN]
Minoxidilum
Minoxidilum [INN-Latin]
Minoxigaine
Minoximen
MolPort-003-666-236
MolPort-005-932-694
NCGC00015673-01
NCGC00015673-02
NCGC00015673-04
NCGC00015673-11
NCGC00018278-01
NCGC00024666-01
NCGC00024666-02
NCGC00024666-03
NCGC00024666-04
NCGC00024666-05
NCGC00024666-06
NCGC00024666-07
NCGC00024666-08
NCGC00179672-01
NINDS_000160
Neoxidil
Normoxidil
Pfizer Brand of Minoxidil
Pierminox
Prestwick0_000020
Prestwick1_000020
Prestwick2_000020
Prestwick3_000020
Prestwick_521
Prexidil
Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide
ROGAINE (FOR MEN)
ROGAINE (FOR WOMEN)
ROGAINE EXTRA STRENGTH (FOR MEN)
Regaine
RiUP
Riup (TN)
Rogaine
Rogaine (TN)
Rogaine Extra Strength for Men
Rogaine for Men
Rogaine for Women
Rogaine, Regaine, Avacor and Mintop, Minoxidil
S1383_Selleck
SAM002589949
SBB056986
SGCUT00112
SMP1_000192
SMR000058963
SMR000326812
SPBio_001006
SPBio_001980
SPECTRUM1500415
Spectrum2_001053
Spectrum3_000509
Spectrum4_000063
Spectrum5_001299
Spectrum_000969
TM-160
Theroxidil
Tocris-0583
Tricoxidil
Trocoxidil
U 10858
U-10,858
U-10858
ZINC00001735
minoxidil
nchembio.79-comp10
to_000070

Interventional clinical trials:

(show top 50)    (show all 215)
idNameStatusNCT IDPhase
1CCB Safety Study in Treatment of Hypertension of ADPKDUnknown statusNCT00541853Phase 4
2Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4
3PROTECT Continued Access Post Marketing Surveillance TrialCompletedNCT00846846Phase 4
4NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by MethylphenidateCompletedNCT00169611Phase 4
5Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypeCompletedNCT00190411Phase 4
6Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDRecruitingNCT02494141Phase 4
7Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Unknown statusNCT02115659Phase 3
8Sirolimus for Massive Polycystic LiverUnknown statusNCT01680250Phase 2, Phase 3
9Open-Label Extension of LOCKCYST TrialUnknown statusNCT00771888Phase 2, Phase 3
10Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3
11Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
12A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3
13A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3
14Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02225860Phase 2, Phase 3
15Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2, Phase 3
16Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
17Open-Label Tolvaptan Study in Subjects With ADPKDCompletedNCT01214421Phase 3
18Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDCompletedNCT00428948Phase 3
19Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2, Phase 3
20HALT Progression of Polycystic Kidney Disease (HALT PKD) Study BCompletedNCT01885559Phase 3
21HALT Progression of Polycystic Kidney Disease (HALT PKD) Study ACompletedNCT00283686Phase 3
22Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2, Phase 3
23Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2, Phase 3
24Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3CompletedNCT01096082Phase 2, Phase 3
25Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT00685373Phase 3
26Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01576367Phase 3
27Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension PhaseCompletedNCT00991146Phase 3
28Efficacy of Riluzole in Hereditary Cerebellar AtaxiaCompletedNCT01104649Phase 2, Phase 3
29Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01302860Phase 3
30Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells SyndromeCompletedNCT00465985Phase 3
31Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaCompletedNCT01850940Phase 3
32An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-HypercholesterolemiaCompletedNCT00694109Phase 3
33Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial HypercholesterolemiaCompletedNCT00607373Phase 3
34Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02055079Phase 3
35Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)RecruitingNCT02964273Phase 3
36The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsRecruitingNCT02134899Phase 3
37Lanreotide In Polycystic Kidney Disease StudyRecruitingNCT02127437Phase 3
38Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiaprideRecruitingNCT00632645Phase 3
39Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT02160145Phase 3
40Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyActive, not recruitingNCT01377246Phase 3
41Study of Lanreotide to Treat Polycystic Kidney DiseaseActive, not recruitingNCT01616927Phase 3
42Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Active, not recruitingNCT01760005Phase 2, Phase 3
43Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT02251275Phase 3
44Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial DiseaseEnrolling by invitationNCT02023866Phase 2, Phase 3
45Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2, Phase 3
46Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2, Phase 3
47PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE InhibitorsTerminatedNCT01583114Phase 3
48Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)TerminatedNCT02106520Phase 2, Phase 3
49Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlUnknown statusNCT01932450Phase 2
50Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)Unknown statusNCT00890279Phase 2

Search NIH Clinical Center for Autosomal Dominant Disease

Genetic Tests for Autosomal Dominant Disease

About this section

Anatomical Context for Autosomal Dominant Disease

About this section

MalaCards organs/tissues related to Autosomal Dominant Disease:

36
Kidney, Liver, Bone, Endothelial, Skin, Heart, Colon

Publications for Autosomal Dominant Disease

About this section

Articles related to Autosomal Dominant Disease:

idTitleAuthorsYear
1
Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease. (27539938)
2016
2
High incidence of pediatric idiopathic epilepsy is associated with familial and autosomal dominant disease in Eastern Newfoundland. (21959335)
2012
3
Challenges of genetic counseling in patients with autosomal dominant diseases, such as the hyper-IgE syndrome (STAT3-HIES). (22981789)
2012
4
Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. (21224835)
2011
5
Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study. (11180447)
2001
6
Quantitative DNA pooling to increase the efficiency of linkage analysis in autosomal dominant disease. (9521591)
1998
7
Nucleus-driven multiple large-scale deletions of the human mitochondrial genome: a new autosomal dominant disease. (1978558)
1990
8
Genetic analysis of familial amyloidotic polyneuropathy, an autosomal dominant disease. (2559819)
1989

Variations for Autosomal Dominant Disease

About this section

Expression for genes affiliated with Autosomal Dominant Disease

About this section
Search GEO for disease gene expression data for Autosomal Dominant Disease.

Pathways for genes affiliated with Autosomal Dominant Disease

About this section

GO Terms for genes affiliated with Autosomal Dominant Disease

About this section

Cellular components related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1chiasmaGO:000571210.6MLH1, MLH3
2male germ cell nucleusGO:000167310.4MLH1, MLH3
3MutSalpha complexGO:003230110.2MSH2, MSH6
4MutLalpha complexGO:003238910.1MLH1, PMS2

Biological processes related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

(show all 49)
idNameGO IDScoreTop Affiliating Genes
1determination of adult lifespanGO:000834011.0MSH2, MSH6
2maintenance of DNA repeat elementsGO:004357011.0MSH2, MSH6
3meiotic mismatch repairGO:000071011.0MSH2, MSH6
4negative regulation of DNA recombinationGO:004591011.0MSH2, MSH6
5positive regulation of helicase activityGO:005109610.9MSH2, MSH6
6dorsal/ventral neural tube patterningGO:002190410.9PTCH1, SHH
7branching involved in prostate gland morphogenesisGO:006044210.9FGFR2, SHH
8branching involved in salivary gland morphogenesisGO:006044510.9FGFR2, SHH
9epithelial cell proliferation involved in salivary gland morphogenesisGO:006066410.9FGFR2, SHH
10limb bud formationGO:006017410.9FGFR2, SHH
11lung-associated mesenchyme developmentGO:006048410.9FGFR2, SHH
12mesenchymal cell proliferation involved in lung developmentGO:006091610.9FGFR2, SHH
13intrinsic apoptotic signaling pathway in response to DNA damageGO:000863010.8MLH1, MSH2, MSH6
14isotype switchingGO:004519010.8MLH1, MSH2, MSH6
15bud elongation involved in lung branchingGO:006044910.8FGFR2, YAP1
16positive regulation of phospholipase activityGO:001051810.8FGFR2, FGFR3
17endochondral bone growthGO:000341610.8FGFR3, MSX2
18pattern specification processGO:000738910.8ALX4, PTCH1, SHH
19digestive tract developmentGO:004856510.8ALX4, FGFR2, TGFBR2
20palate developmentGO:006002110.8ALX4, SHH, TGFBR2
21prostate epithelial cord elongationGO:006052310.8FGFR2, SHH
22anterior/posterior pattern specificationGO:000995210.7ALX4, MSX2, SHH
23embryonic organ developmentGO:004856810.7FGFR2, PTCH1, SHH
24somatic recombination of immunoglobulin genes involved in immune responseGO:000220410.7MLH1, MSH2
25lung developmentGO:003032410.7FGFR2, SHH, TGFBR2
26lung lobe morphogenesisGO:006046310.7FGFR2, SHH, TGFBR2
27embryonic digit morphogenesisGO:004273310.7ALX4, MSX2, SHH
28embryonic forelimb morphogenesisGO:003511510.7ALX4, MSX2, SHH
29embryonic hindlimb morphogenesisGO:003511610.7ALX4, MSX2, SHH
30embryonic limb morphogenesisGO:003032610.7MSX2, PTCH1, SHH
31positive regulation of mesenchymal cell proliferationGO:000205310.7FGFR2, SHH, TGFBR2
32DNA repairGO:000628110.7MLH1, MSH2, MSH6, VCP
33somite developmentGO:006105310.6PTCH1, SHH
34bone morphogenesisGO:006034910.6FGFR2, FGFR3, MSX2
35odontogenesisGO:004247610.6FGFR2, MSX2, SHH
36animal organ morphogenesisGO:000988710.6FGFR2, PAX3, PTCH1, TGFBR2
37trachea morphogenesisGO:006043910.6SHH, TGFBR2
38in utero embryonic developmentGO:000170110.6FGFR2, MSH2, PTCH1, TGFBR2
39somatic recombination of immunoglobulin gene segmentsGO:001644710.6MLH1, MSH2, MSH6
40reciprocal meiotic recombinationGO:000713110.6MLH1, MLH3, MSH2, MSH6
41smoothened signaling pathwayGO:000722410.5PTCH1, SHH, TGFBR2
42mismatch repairGO:000629810.5MLH1, MLH3, MSH2, MSH6, PMS2
43cell-cell signalingGO:000726710.5FGFR2, FGFR3, GJB2, SHH
44somatic hypermutation of immunoglobulin genesGO:001644610.5MLH1, MSH2, MSH6, PMS2
45cellular response to DNA damage stimulusGO:000697410.4MLH1, MLH3, MSH2, VCP, YAP1
46regulation of cell proliferationGO:004212710.3PTCH1, SHH, TGFBR2, YAP1
47positive regulation of cell proliferationGO:000828410.1EPCAM, FGFR2, FGFR3, SHH, TGFBR2, YAP1
48vasculogenesisGO:00015709.9SHH, TGFBR2, YAP1
49positive regulation of transcription from RNA polymerase II promoterGO:00459449.9ALX4, DLX3, EPCAM, FGFR2, PAX3, SHH

Molecular functions related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1four-way junction DNA bindingGO:000040011.0MSH2, MSH6
2MutLalpha complex bindingGO:003240511.0MSH2, MSH6
3oxidized purine DNA bindingGO:003235711.0MSH2, MSH6
4MutSalpha complex bindingGO:003240711.0MLH1, PMS2
5centromeric DNA bindingGO:001923711.0MLH3, MSH2
6patched bindingGO:000511311.0PTCH1, SHH
7fibroblast growth factor-activated receptor activityGO:000500710.9FGFR2, FGFR3
8guanine/thymine mispair bindingGO:003213710.9MLH1, MSH2, MSH6
9mismatched DNA bindingGO:003098310.9MLH3, MSH2, MSH6
10ADP bindingGO:004353110.8MSH2, MSH6, VCP
11single guanine insertion bindingGO:003214210.7MSH2, MSH6
12single thymine insertion bindingGO:003214310.7MSH2, MSH6
13chromatin bindingGO:000368210.5DLX3, MLH1, MLH3, MSH6, YAP1
14ATPase activityGO:001688710.4MLH1, MLH3, MSH2, MSH6, PMS2, VCP
15single-stranded DNA bindingGO:00036979.9MLH1, MLH3, MSH2, PMS2
16ATP bindingGO:00055249.9FGFR2, FGFR3, MLH1, MLH3, MSH2, MSH6
17protein bindingGO:00055157.9ALX4, EPCAM, FGFR2, FGFR3, FTL, GJB2

Sources for Autosomal Dominant Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet